AI in Biotech: Hype, Reality, and the Future of Drug Development

In this episode, Christina Busmalis and Sabine dive deep into the evolving intersection of AI and drug development. They explore the challenges and opportunities posed by digital endpoints, AI in drug discovery, and the growing role of sensors in clinical trials. Christina discusses the complexities of integrating AI in scientific processes, emphasizing the importance of trust in AI-generated data and the validation required to make these tools effective in real-world applications. The conversation also touches on the changing landscape of hiring in the biotech sector, highlighting how new graduates are bringing fresh perspectives and a willingness to embrace technology in scientific research. The episode concludes with insights on fostering collaboration between tech and science teams, with Christina sharing her experiences in bridging the gap between these two worlds at BenevolentAI.

Bio Christina Busmalis

Christina Busmalis is an accomplished technical and sales executive with 30+ years’ experience in a career focused mainly on the Healthcare & Life Science industry, specifically big pharma and BioTech. Most recently, Christina was the Chief Revenue Officer at BenevolentAI, an AI-augmented drug discovery company and was a non-executive board member at the AO Foundation Arbeitsgemeinschaft für Osteosynthesefragen)a nonprofit organization dedicated to improving the care of patients with musculoskeletal injuries or pathologies.  Christina has also held executive leadership positions at Google Cloud, IBM Watson Health, and IBM.  
 

Christina is a computer scientist by education and a consultant by trade. She is an industry thought leader on disruptive technologies for the Life Science industry and a frequent speaker at pharma and digital health-focused conferences across Europe.